Retatrutide
None of the 30 tracked EU+ jurisdictions lists Retatrutide as authorised. This page summarises approval status, brands, shortages and recent regulatory changes by country.
Related regulatory compounds
Country-by-country approval and availability
30 EU+ jurisdictions covered.
No approved pharmaceutical form available.
Updates for Retatrutide
2026-03-19 · 🇪🇺 EU
Retatrutide: TRIUMPH-4 published — 28.7% weight loss
March 2026: full Phase 3 TRIUMPH-4 results from Eli Lilly were published, showing 28.7% average body weight loss — the highest ever recorded in an obesity clinical trial. Seven additional TRIUMPH trials are expected throughout 2026, with NDA filing to the FDA expected in late 2026.
2025-08-15 · 🇪🇺 EU
Retatrutide: remains investigational — Phase 3 ongoing
Retatrutide (Eli Lilly, LY3437943) remains unapproved by FDA/EMA. TRIUMPH (obesity) and TRANSCEND (cardiovascular) Phase 3 programs are ongoing with regulatory submission expected from 2026 onwards.
2024-10-08 · 🇪🇺 EU
Retatrutide: Phase III interim data published
Eli Lilly published Phase III interim showing average -24% body weight at 48 weeks.